Global Bruton Tyrosine Kinase (BTK) Inhibitors Market Report By Type (IC50<1nM, 1nM< IC50<5nM, IC50＞5nM), By Application (Chronic Lymphocytic Leukemia (cll), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Other Selective B Cell Malignancies, Chronic Graft-versus-host Disease, Other) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2021-2028

Name: Global Bruton Tyrosine Kinase (BTK) Inhibitors Market Report
Brand: Value Market Research
SKU: Healthcare
Price: 3950.00 USD
Availability: OnlineOnly
Rating: 4.2 (80 reviews)

ID:VMR11214745

April 2021

Report Formats: Electronic (PDF), MS EXCEL

Description
Table Of Content

The global demand for Bruton Tyrosine Kinase (BTK) Inhibitors Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period 2022 - 2028.

BTK inhibitors are sensitizing agents mainly used in the treatments of hematological malignancies. These novel agents developed to treat various forms of leukemia and lymphoma like non-Hodgkin lymphomas (NHLs) and chronic lymphocytic leukemia, help trigger cell death by blocking the B-cell receptor signaling that the cancer cells use to grow and survive. Some of the BTK inhibitors approved by the FDA are Ibrutinib, Acalabrutinib, and Zanubrutinib. BTK inhibitors have an added advantage over traditional chemotherapy because of their selectivity, which minimizes off-target effects. These drugs create some unique adverse effects, and hence the health care teams need to base their treatment options on patient-specific factors.

Market Dynamics

The growing demand for chemotherapy-free management of B-cell malignancies is the main driver for this market's growth. Several clinical studies to evaluate BTK inhibitors' efficacy to treat various forms of leukemia and lymphoma either as a single medication or in combination with other drugs, chemotherapy, or immunotherapy will broaden the market's scope. Continued research and development of new compounds to achieve better outcomes with fewer unnecessary toxicities will rapidly expand the market. BTK inhibitors' demand to treat autoimmune diseases like multiple sclerosis will continue to grow. They are attractive therapeutic agents that are less likely to trigger antibody responses against the drug and consequent allergic reactions. The high costs and complications like toxicity associated with long-term BTK inhibitor use are the main hindrances to market growth.

The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of bruton tyrosine kinase (btk) inhibitors. The growth and trends of bruton tyrosine kinase (btk) inhibitors industry provide a holistic approach to this study.

Market Segmentation

This section of the bruton tyrosine kinase (btk) inhibitors market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

IC50<1nM
1nM< IC50<5nM
IC50＞5nM

By Application

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Bruton Tyrosine Kinase (BTK) Inhibitors market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

Global Bruton Tyrosine Kinase (BTK) Inhibitors Market Share by Region (Representative Graph)

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the bruton tyrosine kinase (btk) inhibitors market include Johnson & Johnson, AstraZeneca, Roche, Sunesis, Takeda, Bristol- Myers Squibb, Gilead Sciences, AbbVie, Biogen, INNOCARE, ACEA Biosciences, Acerta Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE
       1.1. Report Description
           1.1.1. Objective
           1.1.2. Target Audience
           1.1.3. Unique Selling Proposition (USP) & offerings
       1.2. Research Scope
       1.3. Research Methodology
           1.3.1. Market Research Process
           1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY
       2.1. Highlights of Market
       2.2. Global Market Snapshot

3 . BRUTON TYROSINE KINASE (BTK) INHIBITORS – INDUSTRY ANALYSIS
       3.1. Introduction - Market Dynamics
       3.2. Market Drivers
       3.3. Market Restraints
       3.4. Opportunities
       3.5. Industry Trends
       3.6. Porter’s Five Force Analysis
       3.7. Market Attractiveness Analysis
           3.7.1 By Type
           3.7.2 By Application
           3.7.3 By Region

4 . VALUE CHAIN ANALYSIS
       4.1. Value Chain Analysis
       4.2. Raw Material Analysis
           4.2.1. List of Raw Materials
           4.2.2. Raw Material Manufactures List
           4.2.3. Price Trend of Key Raw Materials
       4.3. List of Potential Buyers
       4.4. Marketing Channel
           4.4.1. Direct Marketing
           4.4.2. Indirect Marketing
           4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
       5.1. Impact Analysis of Covid-19 Outbreak
           5.1.1. Direct Impact on Production
           5.1.2. Supply Chain and Market Disruption
           5.1.3. Financial Impact on Firms and Financial Markets
       5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
       5.3. Market: Pre V/S Post COVID-19
       5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
       5.5. COVID-19: Micro and Macro Factor Analysis

6 . GLOBAL BRUTON TYROSINE KINASE (BTK) INHIBITORS MARKET ANALYSIS BY TYPE
       6.1 Overview by Type
       6.2 Historical and Forecast Data
       6.3 Analysis by Type
       6.4 IC50<1nM Market by Regions
       6.5 1nM< IC50<5nM Market by Regions
       6.6 IC50＞5nM Market by Regions

7 . GLOBAL BRUTON TYROSINE KINASE (BTK) INHIBITORS MARKET ANALYSIS BY APPLICATION
       7.1 Overview by Application
       7.2 Historical and Forecast Data
       7.3 Analysis by Application
       7.4 Chronic Lymphocytic Leukemia (cll) Market by Regions
       7.5 Follicular Lymphoma Market by Regions
       7.6 Mantle Cell Lymphoma Market by Regions
       7.7 Marginal Zone Lymphoma Market by Regions
       7.8 Small Lymphocytic Lymphoma Market by Regions
       7.9 Waldenstrom Macroglobulinemia Market by Regions
       7.10. Other Selective B Cell Malignancies Market by Regions
       7.11 Chronic Graft-versus-host Disease Market by Regions
       7.12 Other Market by Regions

8 . GLOBAL BRUTON TYROSINE KINASE (BTK) INHIBITORS MARKET ANALYSIS BY GEOGRAPHY
       8.1. Regional Outlook
       8.2. Introduction
       8.3. North America
           8.3.1. Overview, Historic and Forecast Data
           8.3.2. North America By Segment
           8.3.3. North America By Country
           8.3.4. United State
           8.3.5. Canada
           8.3.6. Mexico
       8.4. Europe
           8.4.1. Overview, Historic and Forecast Data
           8.4.2. Europe by Segment
           8.4.3. Europe by Country
           8.4.4. United Kingdom
           8.4.5. France
           8.4.6. Germany
           8.4.7. Italy
           8.4.8. Russia
           8.4.9. Rest Of Europe
       8.5. Asia Pacific
           8.5.1. Overview, Historic and Forecast Data
           8.5.2. Asia Pacific by Segment
           8.5.3. Asia Pacific by Country
           8.5.4. China
           8.5.5. India
           8.5.6. Japan
           8.5.7. South Korea
           8.5.8. Australia
           8.5.9. Rest Of Asia Pacific
       8.6. Latin America
           8.6.1. Overview, Historic and Forecast Data
           8.6.2. Latin America by Segment
           8.6.3. Latin America by Country
           8.6.4. Brazil
           8.6.5. Argentina
           8.6.6. Peru
           8.6.7. Chile
           8.6.8. Rest of Latin America
       8.7. Middle East & Africa
           8.7.1. Overview, Historic and Forecast Data
           8.7.2. Middle East & Africa by Segment
           8.7.3. Middle East & Africa by Country
           8.7.4. Saudi Arabia
           8.7.5. UAE
           8.7.6. Israel
           8.7.7. South Africa
           8.7.8. Rest Of Middle East And Africa

9 . COMPETITIVE LANDSCAPE OF THE BRUTON TYROSINE KINASE (BTK) INHIBITORS COMPANIES
       9.1. Bruton Tyrosine Kinase (BTK) Inhibitors Market Competition
       9.2. Partnership/Collaboration/Agreement
       9.3. Merger And Acquisitions
       9.4. New Product Launch
       9.5. Other Developments

10 . COMPANY PROFILES OF BRUTON TYROSINE KINASE (BTK) INHIBITORS INDUSTRY
       10.1. Company Share Analysis
       10.2. Market Concentration Rate
       10.3. Johnson & Johnson
           10.3.1. Company Overview
           10.3.2. Financials
           10.3.3. Products
           10.3.4. Recent Developments
       10.4. AstraZeneca
           10.4.1. Company Overview
           10.4.2. Financials
           10.4.3. Products
           10.4.4. Recent Developments
       10.5. Roche
           10.5.1. Company Overview
           10.5.2. Financials
           10.5.3. Products
           10.5.4. Recent Developments
       10.6. Sunesis
           10.6.1. Company Overview
           10.6.2. Financials
           10.6.3. Products
           10.6.4. Recent Developments
       10.7. Takeda
           10.7.1. Company Overview
           10.7.2. Financials
           10.7.3. Products
           10.7.4. Recent Developments
       10.8. Bristol- Myers Squibb
           10.8.1. Company Overview
           10.8.2. Financials
           10.8.3. Products
           10.8.4. Recent Developments
       10.9. Gilead Sciences
           10.9.1. Company Overview
           10.9.2. Financials
           10.9.3. Products
           10.9.4. Recent Developments
       10.10. AbbVie
           10.10.1. Company Overview
           10.10.2. Financials
           10.10.3. Products
           10.10.4. Recent Developments
       10.11. Biogen
           10.11.1. Company Overview
           10.11.2. Financials
           10.11.3. Products
           10.11.4. Recent Developments
       10.12. Innocare
           10.12.1. Company Overview
           10.12.2. Financials
           10.12.3. Products
           10.12.4. Recent Developments
       10.13. ACEA Biosciences
           10.13.1. Company Overview
           10.13.2. Financials
           10.13.3. Products
           10.13.4. Recent Developments
       10.14. Acerta Pharma
           10.14.1. Company Overview
           10.14.2. Financials
           10.14.3. Products
           10.14.4. Recent Developments

*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

LIST OF FIGURES

Research Scope of Bruton Tyrosine Kinase (BTK) Inhibitors Report
Market Research Process
Market Research Methodology
Global Bruton Tyrosine Kinase (BTK) Inhibitors Market Size, by Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis by Type
Market Attractiveness Analysis by Application
Market Attractiveness Analysis by Region
Value Chain Analysis
Global Market Analysis by Type (USD MN)
IC50<1nM Market by Geography (USD MN)
1nM< IC50<5nM Market by Geography (USD MN)
IC50＞5nM Market by Geography (USD MN)
Global Market Analysis by Application (USD MN)
Chronic Lymphocytic Leukemia (cll) Market by Geography (USD MN)
Follicular Lymphoma Market by Geography (USD MN)
Mantle Cell Lymphoma Market by Geography (USD MN)
Marginal Zone Lymphoma Market by Geography (USD MN)
Small Lymphocytic Lymphoma Market by Geography (USD MN)
Waldenstrom Macroglobulinemia Market by Geography (USD MN)
Other Selective B Cell Malignancies Market by Geography (USD MN)
Chronic Graft-versus-host Disease Market by Geography (USD MN)
Other Market by Geography (USD MN)
Global Market by Revenue
North America Market by Revenue
Europe Market by Revenue
Asia Pacific Market by Revenue
Latin America Market by Revenue
Middle East & Africa Market by Revenue
Recent Development in Industry
Company Market Share Analysis

* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

Choose your Buying Option

Single User License: $ 3950.00

Upto 10 Users License: $ 4950.00

Enterprise License: $ 8600.00

Data Pack: $ 2100.00

Buy Now

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

Buy sections of this report
Buy country level reports
Request for historical data
Request discounts available for Start-Ups & Universities

Request for Special Pricing

Objectives of Study

Define and measure the global market
Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
Analyze and identify major market trends along with the factors driving or inhibiting the market growth
Study the company profiles of the major market players with their market share
Analyze competitive developments

Why Choose Us

Client First Policy

Excellent Quality

After Sales Support

24/7 Email Support

Clients

Testimonials

" Doing business with Value Market Research was – quick, easy and accurate. We got what we expected. The team was very helpful and processes were altered for our convenience. The whole process from understanding our niche requirements to delivery to after sales was excellent. "

Vincenzo Baydar – Head Planning, Leading Food Chain, US

" Excellent work!! Working with you has been easy and direct. Your flexibility to alter the report scope and timely delivery assisted me in delivering my project proposal on time. "

Mia Tang, Director - Business Strategy, Steel Industry, Germany

" This is our second purchase and we have been obliged by the service. We appreciate the efforts put by Value Market Research in terms of understanding our needs, expanding the scope of the study, delivery and handling after sales queries. "